Diagnostic results must be readily available to diagnose critically ill patients in emergency settings and at ICUs. So far, diagnostic blood tests, which demonstrably could help emergency meds recognise residual congestion in heart failure, septic shock, or acute kidney injury before patients reach critical condition, have not been available in the automated format required at ICUs. After Sphingotec acquired Nexus IB-10 POC testing platform in May, investors wait in line.
Investors pool €27m for new Proteomics tech
Latest NewsUK-based biotech startup Fluidic Analytics has raised €27m for its proteomics platform. The financing round was led by Draper Esprit, with participation from Delin Ventures, BGF, IQ Capital, and Amadeus Capital Partners.
Closing a gap at ICUs
BackgroundDiagnostic results must be readily available to diagnose critically ill patients in emergency settings and at ICUs. So far, diagnostic blood tests, which demonstrably could help emergency meds recognise residual congestion in heart failure, septic shock, or acute kidney injury before patients reach critical condition, have not been available in the automated format required at ICUs. After Sphingotec acquired Nexus IB-10 POC testing platform in May, investors wait in line.
Carbios set to build closed-loop PET plant
Latest NewsFrench Carbios SA has signed a letter of intent with PVC giant Kem One to implement a demonstration plant to provide proof of concept of Carbios groundbreaking enzymatic PET depolymerisation technology.
Adrenomed bags €24m in growth financing
Latest NewsGerman Adrenomed AG has bagged €24m in equity financing from HBM Healthcare Investments and Wellington Partners.
Roche targets asthma with inhalable JAK1 blocker
Latest NewsResearchers at Genentech have locally blocked lung inflammation in a mouse model for asthma by administration of an inhalable JAK1 inhibitor.
Merck appoints Jasper Bos as Managing Director of M Ventures
AppointmentsMerck today announced the appointment of Jasper Bos as the new Managing Director of its strategic corporate venture capital arm M Ventures.
British F2G Biotech bags €24m
Latest NewsThe European Investment Bank (EIB) has lent antiinfectives company F2G Biotech Ltd €24m for antifungal research and innovation under the InnovFin Infectious Diseases Finance Facility (IDFF).
Bergenbio appoints Alan Barge MD as interim CMO
AppointmentsBergenbio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, oral, selective AXL kinase inhibitors for multiple cancer indications, has announced the appointment of Alan Barge MD as Interim Chief Medical Officer and member of the leadership team.
Sugar replacement slows cancer growth
Latest NewsResearchers at Cancer UK have slowed down tumour growth by simply feeding mice that carry human tumour xenografts with mannose instead of glucose.
Vertical integration: time is money
BackgroundFinancial pressure on Big Pharma and biotechs increases the need for drug developers to outsource their development and manufacturing capabilities. The CDMO and CRO sector, which is further consolidating through M&A, looks well set for continued growth. As developers have to balance the need to reduce their development risk with time to market or – for biotechs – time to next financing, contract manufacturing and contract research companies clearly favour offering fully integrated services.